Answering the unanswered questions: Ongoing trials of statins and antihypertensives in type 2 diabetes

Acta Diabetologica

Volumn 39, Issue SUPPL. 2, 2002, Pages

  Scott, R ^a  

^a PFIZER INC   (United States)

Author keywords

Amlodipine; Atorvastatin; Calcium channel blockers; Diabetes; Dyslipidaemia; Hypertension; Statins

Indexed keywords

AMLODIPINE; ANTIHYPERTENSIVE AGENT; ANTILIPEMIC AGENT; ATORVASTATIN; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; SIMVASTATIN; 3 HYDROXY 3 METHYLGLUTARYL COENZYME A; AMLODIPINE BESYLATE; ATENOLOL; BENDROFLUMETHIAZIDE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CHLORTALIDONE; DIURETIC AGENT; LISINOPRIL; PERINDOPRIL; PLACEBO;

ANTIHYPERTENSIVE THERAPY; BLOOD PRESSURE REGULATION; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL TRIAL; COMORBIDITY; CONFERENCE PAPER; DRUG EFFICACY; DRUG SAFETY; DYSLIPIDEMIA; HUMAN; HYPERTENSION; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIMARY PREVENTION; PRIORITY JOURNAL; SECONDARY PREVENTION; ATHEROSCLEROSIS; DRUG EFFECT; ISCHEMIC HEART DISEASE; POSTMENOPAUSE;

ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; CLINICAL TRIALS; DIABETES MELLITUS, TYPE 2; DIABETIC ANGIOPATHIES; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERTENSION;

EID: 0036938697     PISSN: 09405429     EISSN: None     Source Type: Journal    
DOI: 10.1007/s005920200026     Document Type: Conference Paper

References (29)

1. King H, Aubert RE, Herman W (1998) Global burden of diabetes, 1995-2025: prevalence, numerical estimates, and projections. Diabetes Care 21:1414-1431
2. Gu K, Cowie CC, Harris MI (1999) Diabetes and decline in heart disease mortality in US adults. JAMA 281:1291-1297
3. Haffner SM, Lehto S, Ronnemaa T, Pyörälä K, Laasko M (1998) Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med 339:229-234
4. Miettinen H, Lehto S, Salomaa VV, Mähönen M, Niemalä M, Haffner SM, Pyörälä K, Tuomilehto J (1998) Impact of diabetes on mortality after the first myocardial infarction. Diabetes Care 21:69-75
5. Downs JR, Clearfield M, Weis S, Whitney E, Shapiro DR, Beere PA, Langendorfer A, Stein EA, Kruyer W, Gotto AM Jr (1998) Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA 279:1615-1622
6. Scandinavian Simvastatin Survival Group (1994) Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease. Scandinavian Simvastatin Survival Study (4S). Lancet 344:1383-1389
7. Pyörälä K, Pedersen TR, Kjekshus J, Faergeman O, Olsson AG, Thorgeirsson G for the Scandinavian Simvastatin Survival Study (4S) Group (1997) Cholesterol lowering with simvastatin improves prognosis of diabetic patients with coronary heart disease. A subgroup analysis of the Scandinavian Simvastatin Survival Study (4S). Diabetes Care 20:614-620
8. Sacks FM, Pfeffer MA, Moyé LA, Rouleau JL, Rutherford JD, Cole TG, Brown L, Warnica JW, Arnold JM, Wun CC, Davis BR, Braunwald E, for the Cholesterol and Recurrent Events Trial Investigators (1996) The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med 335:1001-1009
9. Jones P, Kafonek S, Laurora I, Hunninghake D for the CURVES Investigators (1998) Comparative dose efficacy study of atorvastatin versus simvastatin, pravastatin, lovastatin and fluvastatin in patients with hypercholesterolemia (The CURVES study). Am J Cardiol 81:582-587
10. The Diabetes Atorvastatin Lipid Intervention (DALI) Study Group (2001) The effect of aggressive versus standard lipid lowering by atorvastatin on diabetic dyslipidemia. The DALI study: a double-blind randomized placebo-controlled trial in patients with type 2 diabetes and diabetic dyslipidemia. Diabetes Care 24:1335-1341
11. Gmerek A, McLain R, Nawrocki J (1997) A 4-year, placebo-controlled study of atorvastatin as prevention of CHD endpoints in patients with non-insulin-dependent diabetes mellitus. Diabetes 46[Suppl 1]:363A
12. Wanner C, Krane V, Ruf G, März W, Ritz E, for the Die Deutsche Diabetes Dialyse Study Investigators (1999) Rationale and design of a trial improving outcome of type 2 diabetics on hemodialysis. Kidney Int Suppl 71:S222-S226
13. Brown JH, Hunt LP, Vites NP, Short CD, Gokal R, Mallick NP (1994) Comparative mortality from cardiovascular disease in patients with chronic renal failure. Nephrol Dial Transplant 9:1136-1142
14. LaRosa JC for the TNT Steering Committee (1998) Effect of lowering LDL-C beyond currently recommended minimum targets - the Treating to New Targets (TNT) study. In: Thirteenth International Symposium on Drugs Affecting Lipid Metabolism. 30 May-3 June 1998, Florence, Italy (abstract)
15. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (2001) Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 285:2486-2497
16. American Diabetes Association (2002) Management of dyslipidemia in adults with diabetes. Diabetes Care 25:S74-S77
17. Raggi P, Callister TQ, Davidson M, Welty FK, Bachmann GA, Laskey R, Pittman D, Kafonek S, Scott R (2001) Aggressive versus moderate lipid-lowering therapy in postmenopausal women with hypercholesterolemia: Rationale and design of the Beyond Endorsed Lipid Lowering with EBT Scanning (BELLES) trial. Am Heart J 141:722-726
18. Turner RC, Millns H, Neil HA, Stratton IM, Manley SE, Matthews DR, Holman RR (1998) Risk factors for coronary artery disease in non-insulin dependent diabetes mellitus: United Kingdom Prospective Diabetes Study (UKPDS: 23). BMJ 316:823-828
19. UK Prospective Diabetes Study Group (1998) Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ 317:703-713
20. Pitt B, Byington RP, Furberg CD, Hunninghake DB, Mancini GB, Miller ME, Riley W (2001) Effect of amlodipine on the progression of atherosclerosis and the occurrence of clinical events. PREVENT Investigators. Circulation 102:1503-1510
21. Jorgensen B, Simonsen S, Endresen K, Forfang K, Vatne K, Hansen J, Webb J, Buller C, Goulet G, Erikssen J, Thaulow E (2000) Restenosis and clinical outcome in patients treated with amlodipine after angioplasty: results from the Coronary AngioPlasty Amlodipine REStenosis Study (CAPARES). J Am Coll Cardiol 35:592-599
22. Davis BR, Cutler JA, Gordon DJ, Furberg CD, Wright JT Jr, Cushman WC, Grimm RH, LaRosa J, Whelton PK, Perry HM, Alderman MH, Ford CE, Oparil S, Francis C, Proschan M, Pressel S, Black HR, Hawkins CM (1996) Rationale and design for the Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Am J Hypertens 9:342-360
23. Barzilay JI, Jones CL, Davis BR, Basile JN, Goff DC, Ciocon JO, Sweeney ME, Randall OS (2001) Baseline characteristics of the diabetic participants in the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). Diabetes Care 24:654-658
24. Sever PS, Dahlöf B, Poulter NR, Wedel H, Beevers G, Caulfield M, Collins R, Kjeldsen SE, McInnes GT, Mehlsen J, Nieminen M, O'Brien E, Ostergren J, for the ASCOT Investigators (2001) Rationale, design, methods and baseline demography of participants of the Anglo-Scandinavian Cardiac Outcomes Trial. J Hypertens 19:1139-1147
25. Borghi C, Prandin MG, Costa FV, Bacchelli S, Degli Esposti D, Ambrosioni E (2000) Use of statins and blood pressure control in treated hypertensive patients with hypercholesterolemia. J Cardiovasc Pharmacol 35:549-555
26. Mullen MJ, Wright D, Donald AE, Thorne S, Thomson H, Deanfield JE (2000) Atorvastatin but not L-arginine improves endothelial function in type I diabetes mellitus: a double-blind study. J Am Coll Cardiol 36:410-416
27. Nickenig G, Baumer AT, Temur Y, Kebben D, Jockenhovel F, Bohm M (1999) Statin-sensitive dysregulated AT1 receptor function and density in hypercholesterolemic men. Circulation 100:2131-2134
28. Megnien JL, Levenson J, Del-Pino M, Simon A (1995) Amlodipine induces a flow and pressure-independent vasoactive effect on the brachial artery in hypertension. Br J Clin Pharmacol 39:641-649
29. Leibovitz E, Hazanov N, Zimlichman R, Shargorodsky M, Gavish D (2001) Treatment with atorvastatin improves small artery compliance in patients with severe hypercholesterolemia. Am J Hypertens 14:1096-1098